MAAB Group Announces Strategic Partnership to Commercialise Sancuso® in Greater China

[Auckland, New Zealand] — MAAB Group today announced the signing of a strategic licensing agreement to bring Sancuso® (granisetron transdermal system) across Greater China. Under the agreement, MAAB will assume exclusive manufacturing and commercialisation rights for Sancuso® in the region. The company plans to establish local production capacity in China to improve accessibility for patients and ensure a stable, cost-efficient supply chain.

Sancuso^® Relaunch Marks First Step of Collaboration

The partnership will begin with the manufacturing and relaunch of Sancuso^® across Mainland China, Hong Kong, Macau, and Taiwan. Sancuso^® is a transdermal patch that delivers granisetron to prevent chemotherapy‑induced nausea and vomiting (CINV). It is an internationally approved and marketed product, having received regulatory approvals from the U.S. FDA, the European Medicines Agency (EMA), and China’s NMPA.

Since its original launch over a decade ago, Sancuso^® has played an important clinical role for cancer patients who experience difficulty swallowing, have trouble maintaining oral intake, or require extended antiemetic coverage. Its relaunch in the region, supported by local manufacturing in China, aims to enhance patient access and ensure a stable and cost-efficient supply in the region.

Complementary Strengths for Regional Impact

This partnership unites two organisations with a shared vision and complementary strengths. Both MAAB and Solasia have extensive experience licensing assets from global pharmaceutical innovators and navigating the complexities of regulatory approval, localization, and market access in two of the world’s most important healthcare markets: Japan and China.

Beyond geographic complementarity, the collaboration reflects distinct and synergistic capabilities: Solasia brings deep scientific and clinical development expertise, while MAAB offers strong commercial acumen, strategic networks, and access to local manufacturing infrastructure through its affiliates in China.

The collaboration on Sancuso^® marks MAAB’s strategic entry into oncology supportive care and reinforces its “China-for-China” approach—bringing globally sourced innovations to Chinese patients by aligning with local regulatory trends, cost considerations, and health policy priorities.

Comments from Company Representatives

Alex Lou, Managing Director of MAAB Pharma Limited, a MAAB Group company, stated: “We are honoured to partner with Solasia to bring Sancuso^® and future pipeline products to China. This collaboration aligns with MAAB’s mission to serve as a trusted bridge between Western pharmaceutical innovation and China’s dynamic healthcare market. Our investment reflects confidence in the product, the unmet need, and our shared commitment to localization and patient access.”

About MAAB Group

MAAB Group is a boutique investment and commercialisation platform founded by pharmaceutical industry veterans. The company specialises in the cross-border licensing and trade of innovative medical technologies, with a portfolio spanning reflux diagnostics and treatments, neurological AI tools, and next-generation probiotics and microbiome-based therapies.

Founded in 2011 and originally incorporated in Hong Kong, MAAB is now headquartered in New Zealand, with operational presence in Mainland China, the United Kingdom, and Denmark. MAAB partners with innovative companies worldwide to unlock market opportunities through smart localisation, regulatory strategy, and commercial partnerships.